Effect of combining serum alpha-fetoprotein with LI-RADS v2018 on gadoxetate-enhanced MRI in the diagnosis and prognostication of hepatocellular carcinoma

被引:0
|
作者
Kim, Dong Hwan [1 ,2 ]
Choi, Sang Hyun [1 ,2 ]
Koo, Boyeon [1 ,2 ,3 ]
Choi, Se Jin [1 ,2 ]
Jang, Hyeon Ji [1 ,2 ]
Heo, Subin [1 ,2 ]
Byun, Jae Ho [1 ,2 ]
Won, Hyung Jin [1 ,2 ]
Shin, Yong Moon [1 ,2 ]
机构
[1] Univ Ulsan, Asan Med Ctr, Dept Radiol, Coll Med, Seoul, South Korea
[2] Univ Ulsan, Res Inst Radiol, Asan Med Ctr, Coll Med, Seoul, South Korea
[3] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Radiol, Sch Med, Seoul, South Korea
关键词
Liver; Liver neoplasms; Magnetic resonance imaging; Diagnosis; Prognosis; MANAGEMENT; GUIDELINES; ACID;
D O I
10.1007/s00330-025-11418-2
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives To evaluate the performance of combining serum alpha-fetoprotein (AFP) with LI-RADS (LI-RADS + AFP) on gadoxetate-enhanced MRI for diagnosing hepatocellular carcinoma (HCC) <= 3.0 cm and predicting post-surgical patient outcomes, compared to LI-RADS v2018. Methods Patients with hepatic observations <= 3.0 cm who underwent preoperative gadoxetate-enhanced MRI and surgical resection were retrospectively analyzed. In LI-RADS + AFP, LR-4 (probably-HCC), LR-M (probably or definitely-malignant but not HCC specific), or LR-TIV (definite-tumor-in-vein) by LI-RADS v2018 was upgraded to LR-5 (definitely-HCC) if they met AFP criteria based on three different cut-offs (>= 20, >= 200, >= 400 ng/mL). The sensitivity, specificity, and accuracy of LI-RADS v2018 LR-5 and LI-RADS + AFP LR-5 were compared using generalized estimating equations. Recurrence-free survival (RFS) and overall survival (OS) in the two groups (LR-4/5 vs. LR-M) of LI-RADS v2018 and LI-RADS + AFP were compared using log-rank tests. Results In 520 observations from 414 patients (mean age, 60 +/- 9 years; 328 men), LI-RADS + AFP >= 20 ng/mL (LI-RADS + AFP20) showed the highest accuracy among the three cut-offs. Compared to LI-RADS v2018, LI-RADS + AFP20 showed significantly higher sensitivity in diagnosing HCC (79.9% [95% confidence interval, 75.7-83.6] vs. 71.8% [67.2-76.1], p < 0.001) and accuracy (82.7% [79.2-85.9] vs. 76.9% [73.1-80.5], p < 0.001) without difference in specificity (93.5% [87.1-97.4] vs. 96.3% [90.8-99.0], p = 0.083). Unlike LI-RADS v2018, showing no difference in RFS between LR-4/5 and LR-M (50.6 vs. 42.6 months; p = 0.078), LI-RADS + AFP20 showed significant differences in RFS (50.6 vs. 35.0 months; p < 0.001) and OS (67.6 vs. 54.8 months, p = 0.008). Conclusion Combining AFP and LI-RADS v2018 resulted in better diagnostic performance and superior post-surgical prognostication compared to LI-RADS v2018 alone.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Extended application of subtraction arterial phase imaging in LI-RADS version 2018: a strategy to improve the diagnostic performance for hepatocellular carcinoma on gadoxetate disodium-enhanced MRI
    Kim, Seung-seob
    Lee, Sunyoung
    Bae, Heejin
    Chung, Yong Eun
    Choi, Jin-Young
    Park, Mi-Suk
    Kim, Myeong-Jin
    EUROPEAN RADIOLOGY, 2021, 31 (03) : 1620 - 1629
  • [42] LI-RADS v2018: utilizing ancillary features on gadoxetic acid-enhanced MRI to improve the diagnostic performance of small hapatocellular carcinoma (≤ 20 mm)
    Rong Lyu
    Weijuan Hu
    Di Wang
    Jiao Wang
    Zhongsong Gao
    Kefeng Jia
    Abdominal Radiology, 2023, 48 : 1987 - 1994
  • [43] A gadoxetic acid-enhanced MRI-based multivariable model using LI-RADS v2018 and other imaging features for preoperative prediction of macrotrabecular-massive hepatocellular carcinoma
    Liang, Yingying
    Xu, Fan
    Wang, Zihua
    Tan, Caihong
    Zhang, Nianru
    Wei, Xinhua
    Jiang, Xinqing
    Wu, Hongzhen
    EUROPEAN JOURNAL OF RADIOLOGY, 2022, 153
  • [44] Additional value of 10-min far-delayed phase in extracellular contrast agent-enhanced MRI for diagnostic performance of hepatocellular carcinoma based on LI-RADS v2018
    Wang, Jiahui
    Sun, Wei
    Qiu, Qiansai
    Dong, Sanyuan
    Chen, Xiaoshan
    Wang, Wentao
    Yang, Yutao
    Rao, Shengxiang
    CHINESE JOURNAL OF ACADEMIC RADIOLOGY, 2025, 8 (01) : 24 - 34
  • [45] CT/MRI LI-RADS version 2018 versus CEUS LI-RADS version 2017 in the diagnosis of primary hepatic nodules in patients with high-risk hepatocellular carcinoma
    Lv, Kun
    Cao, Xin
    Dong, Yinlei
    Geng, Daoying
    Zhang, Jun
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (13)
  • [46] Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: An equivalence study using LI-RADS v2018
    Khatri, Gaurav
    Pedrosa, Ivan
    Ananthakrishnan, Lakshmi
    de Leon, Alberto Diaz
    Fetzer, David T.
    Leyendecker, John
    Singal, Amit G.
    Xi, Yin
    Yopp, Adam
    Yokoo, Takeshi
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2020, 51 (02) : 415 - 425
  • [47] Pushing the limit of hepatocellular carcinoma diagnosis: diagnosis of subcentimetre HCC using gadoxetic acid–enhanced MRI and alpha-fetoprotein
    Shin Hye Hwang
    Hyungjin Rhee
    European Radiology, 2024, 34 : 2269 - 2270
  • [48] Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging
    Sun Kyung Jeon
    Ijin Joo
    Dong Ho Lee
    Sang Min Lee
    Hyo-Jin Kang
    Kyoung-Bun Lee
    Jeong Min Lee
    European Radiology, 2019, 29 : 373 - 382
  • [49] Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging
    Jeon, Sun Kyung
    Joo, Ijin
    Lee, Dong Ho
    Lee, Sang Min
    Kang, Hyo-Jin
    Lee, Kyoung-Bun
    Lee, Jeong Min
    EUROPEAN RADIOLOGY, 2019, 29 (01) : 373 - 382
  • [50] Expanding the Liver Imaging Reporting and Data System (LI-RADS) v2018 diagnostic population: performance and reliability of LI-RADS for distinguishing hepatocellular carcinoma (HCC) from non-HCC primary liver carcinoma in patients who do not meet strict LI-RADS high-risk criteria
    Ludwig, Daniel R.
    Fraum, Tyler J.
    Cannella, Roberto
    Tsai, Richard
    Naeem, Muhammad
    LeBlanc, Maverick
    Salter, Amber
    Tsung, Allan
    Fleckenstein, Jaquelyn
    Shetty, Anup S.
    Borhani, Amir A.
    Furlan, Alessandro
    Fowler, Kathryn J.
    HPB, 2019, 21 (12) : 1697 - 1706